Skip to main content

Table 2 Relative expression of tenascin-C, AD1 and AD2 in cell lines and isolated normal breast cells

From: Association of invasion-promoting tenascin-C additional domains with breast cancers in young women

  Number of TNC transcripts (×103) % of total TNC transcripts
Cell line Total TNC AD1 AD2 AD1 AD2
ZR-75-1 0 0 0 0 0
T-47D 0 0 0 0 0
MCF-7 0 0 0 0 0
Hs578T 162.651 41.432 14.574 25.47 8.96
MDA-MB-231 1,293.947 44.383 23.821 3.43 1.84
MDA-MB-436 8,409.526 479.824 55.735 5.71 0.66
MDA-MB-468 984.727 89.74 28.784 9.11 2.92
GI-101 1,529.834 143.854 8.433 9.40 0.55
HBL-100 15,017.045 6,671.261 483.212 44.42 3.22
MCF-10A 91.37 7.399 6.933 8.10 7.59
Primary MEC 2,925.394 1,863.143 142.39 63.69 4.87
Primary fibroblasts 5398.821 87.867 98.044 1.63 1.82
  1. Percentage expression of additional domain (AD) 1 and AD2 relative to the invariant exon 17/18 boundary, as a marker of total tenascin-C (TNC) expression, normalised to the hypoxanthine phosphoribosyltransferase 1 control in cell lines and isolated normal breast cells. MEC, myoepithelial cells.